Építés alatt – nem éles oldal
Belépés
Résztvevőt keres2/3. fázis

Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH

A legfontosabb adatok

Ki végzi
Ultragenyx Pharmaceutical Inc
Hol
Columbus és Pittsburgh (Egyesült Államok)Mind a 2 helyszín megnézéseMég 2 másik országban, 3 helyszínen
Állapot
Toboroz
Fázis
2/3. fázis
Résztvevők
36 fő, tervezett
Kezdés
2016. ápr. 25.
Várható befejezés
2029. márc.
A vizsgálat típusa
Beavatkozással járó, 4 csoport
A vizsgált kezelések
  • UX111
  • Prophylactic Immunomodulatory (IM) Therapy
  • Optimized Prophylactic IM Therapy
  • Adjuvant IM Therapy
A regiszteradat frissítve
2026. szeptember 22.

Ki vehet részt

Életkor
Legfeljebb 17 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 27 feltétel megnézéseKevesebb

Ki vehet részt

  • Diagnosis of MPS IIIA confirmed by the following methods:; No detectable or significantly reduced SGSH enzyme activity by leukocyte assay, and; Genomic DNA analysis demonstrating homozygous or compound heterozygous mutations in the SGSH gene (based upon review of documented results from a qualified laboratory, and with confirmation with Medical Monitor)
  • Age:; For Cohort 1-3: From birth (participating sites in USA and Australia) OR 6 months (participating sites in Spain) to 2 years of age with no BSITD-III Cognitive Development Quotient (DQ) requirement, or older than 2 years with a BSITD-III Cognitive DQ of 60 or above (participating sites globally); For Cohort 4 (participating sites in Spain): 3 months to ≤ 2 years of age with no BSITD-III Cognitive DQ requirement or > 2 years of age with a BSITD-III Cognitive DQ ≥ 60 (n = up to 6). Up to 2 additional subjects > 2 years and ≤ 5 years of age with a BSITD-III Cognitive DQ < 60 may also be enrolled. •Subjects must be ≥ 6 months of age before UX111 administration. However, subjects may be consented and initiate relevant Screening Procedures and IM treatment < 6 months of age. Refer to Section 8.2 for relevant screening procedures •For children ≤ 24 months chronological age who were born prematurely, defined as born at < 36 weeks gestational age, the corrected gestational age must be used for determining inclusion •The BSITD-III Cognitive DQ is assessed during the onsite Screening visit, for subjects who require it •The age of the child on the date of the Screening BSITD-III assessment is used to determine the requirement for the BSITD-III Cognitive DQ score
  • Cohort 4 only: Vaccination status based on age according to country-specific guidelines that is up to date 30 days prior to Enrollment as verified by documentation from the subject's primary care physician, and willing to defer vaccines through 6 months after completion of the subject's IM medication, or longer per Principal Investigator (PI) judgment. Emergency use authorization or conditional marketing authorization of coronavirus disease (COVID) vaccines is included unless there is an accepted medical exemption

Ki nem vehet részt

  • Presence of a concomitant medical condition that precludes lumbar puncture or use of anesthetics
  • Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer or precludes the child from participating in the protocol assessments and follow up
  • Cohorts 1-3: Any vaccination with viral attenuated vaccines less than 30 days prior to the scheduled date of treatment (and use of prednisolone)
  • Previous treatment by hematopoietic stem cell transplantation
  • Previous participation in a gene/cell therapy or enzyme replacement therapy (ERT) clinical trial; Cohort 4 only:
  • Unwilling to avoid consumption of grapefruit juice and the use of strong inhibitors of CYP3A4 and/or P-gp (eg, ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin), strong inducers of CYP3A4 and/or P-gp (eg, rifampin, rifabutin, phenobarbital, carbamazepine, or phenytoin), and St. John's Wort from 30 days prior to Screening through completion of the IM regimen
  • Active viral infection based on clinical observations
  • Cohorts 1-3 only: Serology consistent with exposure to human immunodeficiency virus (HIV), or serology consistent with active hepatitis B or C infection, Cohort 4: Current clinically significant infections (including any requiring systemic treatment including, but not limited to, HIV; hepatitis A, B, or C; varicella zosters virus; human T-cell lymphotropic virus type 1 [HTLV-1]; tuberculosis; or COVID-19) that would interfere with participation in the study
  • Bleeding disorder or any other medical condition or circumstance in which a lumbar puncture (for collection of CSF) is contraindicated according to local institutional policy
  • Visual, hearing, or other impairment sufficient to preclude cooperation with neurodevelopmental testing
  • Uncontrolled seizure disorder
  • Subjects with cardiomyopathy or significant congenital heart abnormalities
  • The presence of significant non-MPS IlIA related CNS impairment or behavioral disturbances that would confound the scientific rigor or interpretation of results of the study
  • Known hypersensitivity, that in the judgment of the PI, places the subject at increased risk for adverse effects
  • Cohorts 1 to 3 only: Identification of two nonsense or null variants on genetic testing of the SGSH gene (based upon review of documented results from a qualified laboratory, and with confirmation with Medical Monitor)
  • At least one S298P mutation in the SGSH gene (based upon review of documented results from a qualified laboratory, and with confirmation with Medical Monitor)
  • Cohorts 1 to 3 only: Subjects with total anti-AAV9 antibody titers ≥ 1:100 equivalent to a positive screen as determined by ELISA binding assay in serum
  • Cohorts 1-3: Abnormal laboratory values Grade 2 or higher as defined in common terminology criteria for adverse events (CTCAE) v4.03 for gamma-glutamyl transferase (GGT), total bilirubin, creatinine, hemoglobin, white blood cell (WBC) count, platelet count, prothrombin time (PT) and activated partial thromboplastin time (aPTT), Cohort 4: Any of the following abnormal laboratory values from screening assessment:; Aspartate aminotransferase (AST), alanine aminotransferase (ALT), GGT, and/or alkaline phosphatase ≥ 2 × upper limit of normal (ULN) and/or total bilirubin > 1.5 × ULN; Anemia (hemoglobin < 10 g/dL); Leukopenia or leukocytosis (total WBC count < 3,000/mm3 and > 15,000/mm3 respectively); Abnormal absolute neutrophil count (ANC) of < 1000/mm3; Platelet count < 100,000/mm3; Coagulopathy (international normalized ratio [INR] > 1.5) or aPTT > 40 seconds; Renal impairment, defined as estimated glomerular filtration rate (eGFR) below the lower limit of normal (age and sex appropriate) based on Bedside Schwartz equation
  • Inability to participate in the clinical evaluation as determined by PI
  • Has evidence of an attenuated phenotype of MPS IIIA, in the judgement of the PI
  • Cohorts 1-3 only: Subjects with a positive response for the enzyme-linked immunosorbent spot assay (ELISpot) for T-cell responses to AAV9
  • Any item (braces, etc.) or circumstance that would exclude the subject from being able to undergo MRI according to local institutional policy
  • Any other situation that precludes the subject from undergoing procedures required in this study
  • Female of childbearing potential who is pregnant or demonstrates a positive urine or bhCG result at screening assessment (if applicable)

Helyszínek itt: Egyesült Államok

Még 2 másik országban, 3 helyszínen

  • Nationwide Children's HospitalColumbus, Egyesült ÁllamokNo longer taking part
  • Children's Hospital of PittsburghPittsburgh, Egyesült ÁllamokNo longer taking part

A vizsgálatról

Mit akar kideríteni a vizsgálat

The main objective of this study is to evaluate the efficacy and safety of UX111 for the treatment of MPS IIIA.

A vizsgálat 4 csoportja

  • Cohort 1 Low DoseA vizsgált kezelés

    Dose of 0.5 X 10\^13 vg/kg

    Kezelés: UX111, Prophylactic Immunomodulatory (IM) Therapy és Adjuvant IM Therapy

  • Cohort 2 Mid DoseA vizsgált kezelés

    Dose of 1 X 10\^13 vg/kg

    Kezelés: UX111, Prophylactic Immunomodulatory (IM) Therapy és Adjuvant IM Therapy

  • Cohort 3 High DoseA vizsgált kezelés

    Dose of 3 X 10\^13 vg/kg

    Kezelés: UX111, Prophylactic Immunomodulatory (IM) Therapy és Adjuvant IM Therapy

  • Cohort 4 High Dose (Spain Only)A vizsgált kezelés

    Dose of 3 X 10\^13 vg/kg

    Kezelés: UX111, Optimized Prophylactic IM Therapy és Adjuvant IM Therapy

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA
A regiszteradat frissítve
2026. szeptember 22.